Koers Nivalis Therapeutics Inc Nasdaq
Aandelen
US65481J1097
Biotechnologie & Medisch Onderzoek
Omzet 2025 * | - | Omzet 2026 * | - | Marktkapitalisatie | 4,46 mld. 4,12 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2025 * | - | Nettowinst (verlies) 2026 * | - | EV/omzet 2025 * | - |
Nettoliquiditeiten 2025 * | - 0 | Nettoliquiditeiten 2026 * | - 0 | EV/omzet 2026 * | - |
K/w-verhouding 2025 * |
-
| K/w-verhouding 2026 * |
-
| Werknemers | - |
Dividendrendement 2025 * |
-
| Dividendrendement 2026 * |
-
| Vrij verhandelbaar | 96,04% |
Recentste transcriptie over Nivalis Therapeutics Inc
Vaira. 1 jan. | Kapi. | |
---|---|---|
+19,33% | 125 mld. | |
+13,95% | 108 mld. | |
-3,53% | 24,57 mld. | |
+3,52% | 22,82 mld. | |
-11,25% | 18,19 mld. | |
-41,48% | 16,54 mld. | |
-12,62% | 16,5 mld. | |
+0,99% | 13,39 mld. | |
+21,79% | 11,1 mld. |